French startup Iktos has secured €15.5 million in Collection A funding for its AI-powered drug discovery platform.
The spherical was co-led by M Ventures and Debiopharm Innovation Fund, with participation from Omnes Capital, and can allow Iktos to develop its know-how additional and develop its SaaS software program providing. The corporate is ready to launch Robotics, an end-to-end drug discovery platform that makes use of AI and automation of chemical synthesis to speed up drug discovery timelines.
Moreover, the corporate will develop its utility of options to organic merchandise, permitting it to supply absolutely built-in drug discovery providers to the pharmaceutical trade.
Iktos, which was based in 2016, makes use of a know-how platform for deep learning-based drug design that gives vital productiveness positive factors in upstream pharmaceutical R&D. The platform is accessible as skilled providers and SaaS software program Makya, and Spaya, a synthesis planning software program based mostly on Iktos’ proprietary AI know-how for retrosynthesis. Its AI options will speed up drug discovery whereas growing the probability of drug candidates reaching scientific growth, with collaborations already in place with Janssen, Merck, Pfizer, Servier, Ono, and Teijin.
In accordance with Yann Gaston-Mathé, the President and co-founder of Iktos, “The applying of synthetic intelligence to early drug discovery and design presents the potential for a radical change for researchers exploring such a chemical universe. The applied sciences we have now developed have been enabling a number of companions in realizing this promise. We welcome our new, skilled, investor syndicate and recent financing that may permit us to execute our plan of being the popular accomplice for the trade to handle their drug growth wants.”
In the meantime, Dr. Nadiya Ishnazarova of M Ventures acknowledged, “We consider Iktos with its mature know-how throughout generative AI and synthesis planning, and developments in constructing absolutely built-in drug discovery platform has the potential to supply a aggressive edge for the pharma trade as AI/ML turns into a core function of R&D.”
Tanja Dowe, CEO of Debiopharm Innovation Fund added, “We’re very excited to collaborate with a powerful syndicate of sturdy buyers M Ventures and Omnes Capital to help Iktos in executing its plans to develop cutting-edge end-to-end AIDD capabilities.”
The funding spherical will allow Iktos to proceed to be a most well-liked accomplice for the pharmaceutical trade, and the launch of Robotics will allow the corporate to change into one of many first to supply absolutely built-in drug discovery providers to the sector. With vital advantages already acknowledged in its AI options, Iktos is poised to play a number one function within the AI-powered drug discovery revolution.
